Brokerages expect Medidata Solutions (NASDAQ:MDSO) to announce $0.40 earnings per share for the current fiscal quarter, Zacks reports. Seven analysts have provided estimates for Medidata Solutions’ earnings, with the highest EPS estimate coming in at $0.42 and the lowest estimate coming in at $0.39. Medidata Solutions posted earnings of $0.31 per share in the same quarter last year, which suggests a positive year-over-year growth rate of 29%. The business is scheduled to issue its next earnings results on Tuesday, July 17th.

According to Zacks, analysts expect that Medidata Solutions will report full-year earnings of $1.72 per share for the current fiscal year, with EPS estimates ranging from $1.67 to $1.76. For the next fiscal year, analysts forecast that the company will report earnings of $2.10 per share, with EPS estimates ranging from $1.94 to $2.25. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that follow Medidata Solutions.

Medidata Solutions (NASDAQ:MDSO) last issued its quarterly earnings data on Thursday, April 19th. The company reported $0.40 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.35 by $0.05. Medidata Solutions had a return on equity of 11.36% and a net margin of 7.96%. The business had revenue of $149.20 million for the quarter, compared to the consensus estimate of $146.73 million. During the same period last year, the business earned $0.31 EPS. The firm’s revenue was up 16.9% compared to the same quarter last year.

A number of research analysts recently weighed in on MDSO shares. TheStreet raised Medidata Solutions from a “c+” rating to a “b-” rating in a research note on Monday, March 12th. Zacks Investment Research raised Medidata Solutions from a “hold” rating to a “buy” rating and set a $70.00 price objective on the stock in a research note on Wednesday, February 14th. Needham & Company LLC cut their price objective on Medidata Solutions to $75.00 and set a “buy” rating on the stock in a research note on Friday, February 9th. BidaskClub raised Medidata Solutions from a “hold” rating to a “buy” rating in a research note on Friday, May 4th. Finally, Dougherty & Co reissued a “buy” rating and issued a $89.00 price objective (up from $79.00) on shares of Medidata Solutions in a research note on Thursday, May 10th. Five equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $84.50.

In other Medidata Solutions news, CEO Tarek Sherif sold 26,836 shares of Medidata Solutions stock in a transaction that occurred on Monday, March 12th. The stock was sold at an average price of $70.25, for a total value of $1,885,229.00. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Rouven Bergmann sold 2,000 shares of Medidata Solutions stock in a transaction that occurred on Monday, March 19th. The stock was sold at an average price of $66.30, for a total value of $132,600.00. Following the completion of the transaction, the chief financial officer now directly owns 94,744 shares in the company, valued at $6,281,527.20. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 46,231 shares of company stock worth $3,258,559. Company insiders own 4.70% of the company’s stock.

Several large investors have recently made changes to their positions in the company. Clearbridge Investments LLC grew its holdings in shares of Medidata Solutions by 0.4% during the 4th quarter. Clearbridge Investments LLC now owns 2,171,755 shares of the company’s stock worth $137,624,000 after purchasing an additional 9,425 shares in the last quarter. Champlain Investment Partners LLC grew its holdings in shares of Medidata Solutions by 15.7% during the 1st quarter. Champlain Investment Partners LLC now owns 2,148,615 shares of the company’s stock worth $134,955,000 after purchasing an additional 291,630 shares in the last quarter. American Century Companies Inc. grew its holdings in shares of Medidata Solutions by 0.3% during the 1st quarter. American Century Companies Inc. now owns 1,444,426 shares of the company’s stock worth $90,724,000 after purchasing an additional 4,716 shares in the last quarter. Global Thematic Partners LLC grew its holdings in shares of Medidata Solutions by 37.3% during the 4th quarter. Global Thematic Partners LLC now owns 1,429,138 shares of the company’s stock worth $90,564,000 after purchasing an additional 388,608 shares in the last quarter. Finally, Disciplined Growth Investors Inc. MN grew its holdings in shares of Medidata Solutions by 12.2% during the 1st quarter. Disciplined Growth Investors Inc. MN now owns 932,254 shares of the company’s stock worth $58,555,000 after purchasing an additional 101,398 shares in the last quarter.

Shares of Medidata Solutions traded down $0.76, reaching $75.33, during trading on Friday, MarketBeat.com reports. The company had a trading volume of 425,356 shares, compared to its average volume of 652,970. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.63 and a current ratio of 1.63. Medidata Solutions has a one year low of $59.60 and a one year high of $85.92. The company has a market capitalization of $4.46 billion, a price-to-earnings ratio of 88.62, a PEG ratio of 3.78 and a beta of 1.49.

About Medidata Solutions

Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development of new therapies. The company's platform solutions include data capture and management and trial planning and management.

Get a free copy of the Zacks research report on Medidata Solutions (MDSO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.